Keyphrases
Crohn's Disease
100%
Systematic Meta-analysis
62%
Inflammatory Bowel Disease
51%
Meta-analysis
35%
Corticosteroids
34%
Adalimumab
34%
Ustekinumab
34%
Capsule Endoscopy
31%
Small Bowel Crohn's Disease
31%
Anti-adalimumab Antibodies
31%
Pooled Analysis
31%
Odds Ratio
30%
Confidence Interval
29%
Real-world Experience
28%
Clinical Response
22%
Immunogenicity
22%
Vedolizumab
21%
Diagnostic Performance
19%
Immunomodulator
19%
Small Intestine
18%
Randomized Controlled Trial
18%
Hospitalized Patients
17%
Low Albumin
17%
Clinical Activity
17%
Loss of Response
16%
Antibody Formation
16%
Time Dependency
15%
Place in Therapy
15%
Three-dimensional Endoanal Ultrasound
15%
3D Endoanal Ultrasound
15%
Treatment Efficacy
15%
Reporting Odds Ratio
15%
Phrasing
15%
Web Platform
15%
Novel Biomarkers
15%
Syndecan-1
15%
Neoplasia
15%
Poeticity
15%
Narrow Band Imaging
15%
Crowdsourcing
15%
Simple Tools
15%
Neutrophil-to-lymphocyte Ratio
15%
Fecal Calprotectin
15%
5-aminosalicylic Acid (5-ASA)
15%
Magnetic Resonance Enterography
15%
Non-adherence
15%
Drug Concentration
15%
Cytomegalovirus
15%
Adherence to Therapy
15%
Small Bowel Adenocarcinoma
15%
Medicine and Dentistry
Crohn's Disease
62%
Systematic Review
46%
Inflammatory Bowel Disease
41%
Odds Ratio
38%
Diagnosis
36%
Meta-Analysis
35%
Capsule Endoscopy
31%
Ulcerative Colitis
31%
Immunomodulating Agent
18%
Patient with Inflammatory Bowel Disease
17%
Biological Marker
16%
Hip Fracture
15%
Rehabilitation Engineering
15%
Ibuprofen
15%
Narrow Band Imaging
15%
Cytomegalovirus
15%
Faecal Calprotectin
15%
Corticosteroid Therapy
15%
Neoplasm
15%
Neutrophil
15%
Magnetic Resonance Enterography
15%
Vedolizumab
15%
Internal Anal Sphincter
15%
Syndecan 1
15%
Cerebral Sinus Thrombosis
15%
Adalimumab
15%
Aminosalicylic Acid Derivative
15%
Pancreas Adenocarcinoma
15%
White Light Endoscopy
15%
Chromoendoscopy
15%
Lymphocyte
15%
Pooled Analysis
15%
Adenocarcinoma
15%
Acute Pancreatitis
15%
Disease
15%
Coronavirinae
15%
Nilotinib
15%
Feces Incontinence
11%
Infection
10%
Thrombosis
9%
Muscle Injury
7%
Calgranulin
7%
Muscle Disease
7%
Injury
7%
Salvage Therapy
7%
Adverse Event
7%
Mortality Rate
6%
Retrospective Study
6%
Combination Therapy
5%
Diagnostic Accuracy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
70%
Ulcerative Colitis
51%
Inflammatory Bowel Disease
50%
Adalimumab
31%
Ustekinumab
31%
Aminosalicylic Acid
31%
Disease
20%
Immunogenicity
19%
Immunomodulating Agent
18%
Randomized Controlled Trial
18%
Hip Fracture
15%
Ibuprofen
15%
Acute Pancreatitis
15%
Coronavirinae
15%
Prospective Study
15%
Nilotinib
15%
Drug Concentration
15%
Inflammation
15%
Vedolizumab
15%
Enteropathy
15%
Infection
12%
Adverse Event
12%
Remission
11%
Biological Product
10%
Combination Therapy
8%
Infliximab
8%
Mortality Rate
7%
Pancreatitis
5%
Disease Course
5%
